MOBIO St. Louis Life Sciences Dinner - Register Today (Link)
Make plans to join MOBIO and our distinguished guests for an industry-wide dinner of the bioscience community. MOBIO is excited to welcome Dr. Stephen Ostroff, M.D. to St. Louis. Dr. Ostroff is the United States Food and Drug Administration's Acting Commissioner of Food And Drugs. As the top official of the FDA, Dr. Ostroff is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health. Dr. Ostroff is expected to highlight recent FDA accomplishments and the agency's efforts to evolve scientifically with precision medicine and agriculture.
In addition, MOBIO is honored to welcome Congressman Billy Long from Missouri's 7th Congressional District. Rep. Long is a member of the House Energy and Commerce Committee and serves on three critical Energy and Commerce Subcommittees: Communications and Technology; Energy and Power; and Health.
We appreciate these guests taking the time to join us for this very important and meaningful gathering.
Thursday, October 1, 2015
The Ritz Carlton Ballroom
100 Carondelet Plaza
Clayton, MO 63105
Dinner Gold Sponsor..........................$10,000
Dinner Silver Sponsor.........................$5,000
MOBIO Life Sciences Summit, Headed to Columbia - Register Today (Link)
MOBIO's Life Sciences Summit will serve to connect the state's biotechnology leaders, researchers, economic developers, elected officials and decision-makers in order to advance a stronger collaborative posture for Missouri's bioscience industry.
November 9 & 10, 2015
From 5:00pm Monday to 5:00pm Tuesday
The Broadway Doubletree Columbia
1111 E. Broadway
Kansas City University of Medicine and Biosciences (KCU), the largest medical school in Missouri and one of the oldest osteopathic medical schools in the country, announced that John Dougherty, D.O., will serve as interim dean for KCU’s new
osteopathic medical school in Joplin, Mo.
“I’m honored and excited to be selected as interim dean for KCU’s new campus in Joplin,” said Dr. Dougherty. “This is an important time at KCU — and in osteopathic medicine. The new campus in Joplin will be uniquely positioned to have a significant impact on the need for primary care physicians to serve in rural and underserved areas in this region.”
Dr. Dougherty is currently senior associate dean for clinical affairs and graduate medical education for KCU at its Kansas City, Mo., campus. He has a bachelor of science in biology and education from Culver Stockton College and received his doctor of osteopathy from KCU in 1992. He previously served as acting dean at KCU and as chair of the department of family medicine.
One of the more heartbreaking realities of Alzheimer's is the moment when a loved one struggling with the disease no longer fully recognizes a family member or close friend who is caring for them.
Now, new research from Washington University in St. Louis has identified a novel learning and memory brain network that processes incoming information based on whether it's something we've experienced previously or is deemed to be altogether new and unknown, helping us recognize, for instance, whether the face before us is that of a familiar friend or a complete stranger.
Forthcoming in the September issue of the journal Trends in Cognitive Sciences, the study pulls together evidence from multiple neuroimaging studies and methods to demonstrate the existence of previously unknown and distinct functional brain network, one that appears to have broad involvement in human memory processing.
Wexford Science + Technology LLC, a BioMed Realty Company, announced that Evogene, a plant genomics company based in Israel, is establishing its U.S. headquarters in the Bio Research & Development Growth (BRDG) Park on the campus of the Donald Danforth Plant Science Center in St. Louis, Missouri.
“We are very pleased with the continued success in attracting global companies to BRDG Park at the Danforth Center. Evogene is a great addition to the growing plant and ag science ecosystem that is driving research, discovery, innovation and entrepreneurism in the St. Louis region,” said Jim Berens, president, Wexford Science +Technology.
Evogene, a leading company for the improvement of crop productivity, works with the world's leading agriculture companies to develop improved seed traits in crops like corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection.
Biopharmaceutical innovation means more than helping patients lead longer, healthier, more productive lives. Through the continued development of new treatments and cures, each discovery contributes valuable knowledge to the research and development process--improving patients’ lives, advancing medical innovation and fueling economic growth. Take a look below at the positive impact the process of finding new treatments and cures has on our everyday lives.
Working for Patients
Did you know that medicines have helped raise average U.S. life expectancy to 78 years from 47 years? Biopharmaceutical companies create medicines that provide patients with hope and new treatments are increasing survival rates and raising cure rates for various cancers and other diseases. For example, new hepatitis C therapies have yielded a cure rate exceeding 90 percent.
Most people do not stop to think about what it takes to bring a new medicine to market. On average it takes more than 10 years and costs $2.6 billion to research and development a new medicine. With more than 500 new medicines approved by the U.S. Food and Drug Administration since 2000, significant advancements are typically the result of cumulative innovation over time.
Improving Health Care
Medicines allow patients to live longer and healthier lives as well as avoid expensive hospital care by slowing, treating and curing diseases. For example, if non-adherent patients with diabetes were to become adherent and follow their doctor’s treatment plan, hospitalizations and emergency room visits could be avoided and yield nearly $5 billion in medical savings.
Strengthening Our Economy
The biopharmaceutical sector drives economic growth in the US, with an overall economic impact of $789 billion on an annual basis. More than 810,000 people work in the biopharmaceutical industry in the US and contribute to its significant work.
Six years ago we saw a need to establish a gathering of innovators, investors, and others in the ag-tech space. We are proud to report that since that time the Ag Innovation Showcase has established a loyal following and community. Beginning with the first Ag Innovation Showcase in 2009, we have featured panels and presentations that address important topics including the development of biofuels and biomaterials, advances in biotechnology, progress in animal health, and, more recently the great changes facing the future of agriculture and the role of biotechnology in agriculture.
As the premier event where Ag’s biggest names, brightest innovators & most influential investors connect, we encourage the convergence of diverse technology solutions around platforms to help bring the industry to the next level of productivity and sustainability. We are confident in continuing the tradition of creative thinking directed toward profound challenges and great opportunities in agriculture, and we invite you to stay tuned for the 2015 Showcase and the activities to ensue between.
The Ag Innovation Showcase is a joint effort of the Bio Research & Development Growth (BRDG) Park, the Donald Danforth Plant Science Center and the Larta Institute.
Monday, September 14 - Wednesday, September 16, 2015
Donald Danforth Plant Science Center
St. Louis, Missouri
Are you a MOBIO member & would like your event featured? If so, please forward all event details or links to Tony Dunavant via email to email@example.com.